Quick Answer
NYMOX PHARMACEUTICAL CORP reported Total Assets of $654.0 thousand for fiscal year 2024.
NYMOX PHARMACEUTICAL CORP — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Assets | $654.0K +4.3% |
$627.0K -61.4% |
$1.62M +12.6% |
$1.44M -66.8% |
$4.34M -20.9% |
$5.49M -32.0% |
| R&D Expense | $3.28M -17.9% |
$3.99M +5.9% |
$3.77M -43.3% |
$6.66M -18.0% |
$8.12M +10.1% |
$7.38M +10.5% |
- NYMOX PHARMACEUTICAL CORP reported Total Assets of $654.0 thousand for fiscal year 2024.
- NYMOX PHARMACEUTICAL CORP showed an increase of +4.3% in Total Assets compared to the prior fiscal year.
- NYMOX PHARMACEUTICAL CORP reported R&D Expense of $3.28 million for fiscal year 2024.
- NYMOX PHARMACEUTICAL CORP showed a decrease of -17.9% in R&D Expense compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: